Emerald Health Biotechnology
2003
FOUNDED
M&A
STATUS
1-10
EMPLOYEES
M&A
LATEST DEAL TYPE
2
FINANCING ROUNDS
Description
Developer of pharmaceutical drugs created to focus on new non-psychotropic cannabinoids for the treatment of inflammatory and neurodegenerative diseases. The company's operations include development of cannabidiol and cannabigerol chemical derivatives that improve the therapeutic properties of the natural hit compounds which addresses unmet clinical need in the treatment of multiple sclerosis, Huntington's disease and scleroderma.
Website
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Emerald Health Research
Primary Office
- Parque Científico Tecnológico de Córdoba (Rabanales 21)
- Calle Astrónoma Cecilia Payne, Edificio Centauro, Planta 1
- 14014 Córdoba
- Spain
Emerald Health Biotechnology Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Emerald Health Biotechnology‘s full profile, request access.
Request full access to PitchBook